Disclosures for "Description of a Rare Compound Heterozygous Transthyretin Mutation Val30Met/Val122Ile Conferring Early Onset Hereditary Amyloidosis with Severe Features")
-
Dr. Nardin has nothing to disclose.
-
Dr. Traub has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Traub has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Traub has received research support from Alnylam Pharmaceuticals. The institution of Dr. Traub has received research support from Alexion. The institution of Dr. Traub has received research support from Muscular Dystrophy Association (MDA). The institution of Dr. Traub has received research support from Ionis.